jcp conference-coverage

Conference Coverage

Significance of ctDNA Clearance Following Adjuvant Chemotherapy Among Patients with Radically Resected Colorectal Cancer

01/20/2024

Allison Casey

According to updated results from a substudy of the observational GALAXY study, detection of MRD via ctDNA and ctDNA dynamics in response to adjuvant chemotherapy for colorectal cancer were found to be highly prognostic of patient outcomes in...

According to updated results...

01/20/2024

Oncology

Conference Coverage

Role of ctDNA to Guide Adjuvant Chemotherapy Use for Patients With Colon Cancer

01/20/2024

Allison Casey

In the phase 2/3 COBRA study no improvement in ctDNA clearance was observed after 6 months of chemotherapy among patients with ctDNA detected following resection of stage IIA colon cancer.

In the phase 2/3 COBRA study no...

01/20/2024

Oncology

Videos

Outcomes of Men With High-Risk, Biochemically Recurrent Prostate Cancer Who Discontinued Enzalutamide Monotherapy in the EMBARK Study

01/18/2024

Featuring Neal Shore, MD, FACS

Featuring Neal Shore, MD, FACS ...

Neal Shore, MD, FACS, discusses his study on the outcomes of men with high-risk, biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study.

Neal Shore, MD, FACS, discusses...

01/18/2024

Journal of Clinical Pathways

Conference Coverage

Recent Breakthroughs in the Mantle Cell Lymphoma Treatment Landscape

01/08/2024

Featuring Bijal D. Shah, MD

Bijal D. Shah, MD, shares the breakthroughs in the mantle cell lymphoma treatment landscape that he found most promising at the 65th American Society of Hematology (ASH) Annual Meeting.

Bijal D. Shah, MD, shares the...

01/08/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Featuring Douglas Tremblay, MD

Featuring Douglas Tremblay, MD ...

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

The Potential of Pelabresib Plus Ruxolitinib For Treating Patients With Myelofibrosis: The MANIFEST-2 Study

12/08/2023

Edited by: Grace Taylor

A study by Raajit K. Rampal, MD, PhD, and colleagues investigates the effects of pelabresib + ruxolitinib in patients with myelofibrosis who have not been previously treated with a JAK inhibitor.

A study by Raajit K. Rampal, MD,...

12/08/2023

Journal of Clinical Pathways

Conference Coverage

Key Factors Influencing Survival Rates in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

12/07/2023

Edited by Grace Taylor

A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.

A study by Helen Ajufo, MD, MS,...

12/07/2023

Journal of Clinical Pathways

Conference Coverage

Incidence and Survival Outcomes of Diffuse Large B-Cell Lymphoma in Adolescents and Young Adults

12/07/2023

Edited by Grace Taylor

A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.

A team of researchers conducted...

12/07/2023

Journal of Clinical Pathways

Conference Coverage

The Role of Granulocyte Colony-Stimulating Factor in the Treatment of Neutropenia in Patients on Sacituzumab Govitecan and its Impact on Therapy Duration

12/06/2023

Edited by Grace Taylor

Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...

Using data from a real-world...

12/06/2023

Journal of Clinical Pathways

Conference Coverage

Impact of Implementing Universal Germline Genetic Testing for Breast Cancer in Rural Communities

12/06/2023

Edited by Brandon Twyford

New research underscores the high implementation rate and significant impact of universal germline genetic testing (GGT) for breast cancer (BC) in rural medical practices on shared treatment decision-making.

New research underscores the...

12/06/2023

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products